SEARCH:   Advanced

Blood, 1 February 2005, Vol. 105, No. 3, pp. 1153-1161. Prepublished online as a Blood First Edition Paper on September 28, 2004; DOI 10.1182/blood-2004-03-0791. This Article Full Text (PDF) All Versions of this Article: 2004-03-0791v1 105/3/1153    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bots, M. Articles by Medema, J. P Search for Related Content PubMed PubMed Citation Articles by Bots, M. Articles by Medema, J. P Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 2, 2004 Accepted September 16, 2004 SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity Michael Bots, Ingrid G Kolfschoten, Sandra A Bres, Mirjam T Rademaker, Guido M de Roo, Margreet Kruse, Kees L Franken, Michael Hahne, Christopher J Froelich, Cornelis J Melief, Rienk Offringa, and Jan P Medema* Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands Division of Tumor Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, The Netherlands Institut de Genetique Moleculaire de Montpellier, CNRS UMR5535, Montpellier, France Department of Medicine, Evanston Northwestern Healthcare Research Institute, Evanston, IL, USA * Corresponding author; email: jpmedema{at}lumc.nl. Tumors have several mechanisms to escape from the immune system. One of these involves expression of intracellular anti-cytotoxic proteins that modulate the execution of cell death. Previously, we have shown that the serpin SPI-6, which inactivates the cytotoxic protease granzyme B (GrB), is capable of preventing cytotoxic T lymphocyte (CTL)-mediated apoptosis. Despite its potent anti-apoptotic activity, SPI-6 does not prevent membranolysis induced by cytotoxic lymphocytes. We now provide evidence that several colon carcinoma cell lines do resist membranolysis and that this protection is dependent on SPI-6, but also requires expression of a closely related serpin called SPI-CI. Expression of SPI-CI is absent from normal colon, but observed in placenta, testis, early during embryogenesis and in cytotoxic lymphocytes. SPI-CI encodes a chymotrypsin-specific inhibitor and irreversible interacts with purified granzyme M. Moreover, SPI-CI can protect cells from purified perforin/GrM-induced lysis. Our data therefore indicate that SPI-CI is a novel immune escape molecule that acts in concert with SPI-6 to prevent cytotoxic lymphocyte-mediated killing of tumor cells. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. A. Marques, P. S. Hahnel, C. Wolfel, S. Thaler, C. Huber, M. Theobald, and M. Schuler An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression Blood, February 1, 2008; 111(3): 1413 - 1419. [Abstract] [Full Text] [PDF] M. Bots, R. Offringa, J. P. Medema, C. Scheibenbogen, R. Godal, and E. Thiel Does the serpin PI-9 protect tumor cells? Blood, June 15, 2006; 107(12): 4974 - 4975. [Full Text] [PDF] R. Godal, U. Keilholz, L. Uharek, A. Letsch, A. M. Asemissen, A. Busse, I.-K. Na, E. Thiel, and C. Scheibenbogen Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2 Blood, April 15, 2006; 107(8): 3205 - 3211. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020